5,7-difluoro-benzothiazole-2-thiol | 1163123-63-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 5,7-difluoro-benzothiazole-2-thiol
• 英文别名: 5,7-difluoro-3H-1,3-benzothiazole-2-thione
• CAS: 1163123-63-4
• 化学式: C₇H₃F₂NS₂
• 分子量: 203.236
• InChiKey: ZLCCIXVLFOWROQ-UHFFFAOYSA-N

物化性质

• 沸点：
  273.1±50.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5,7-difluoro-benzothiazole-2-thiol 在 N,N-二甲基甲酰胺 氯化亚砜 作用下， 反应 48.0h， 以32.6%的产率得到2-氯-5,7-二氟苯并噻唑
  参考文献：
  名称：

  HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及以下公式的化合物，其中Ar，Het，R1和n的定义如本文所述，并且涉及适用于药物的酸盐、光学纯对映体、拉氏体或其二对映异构体混合物。公式I的化合物是促进睡眠激素受体拮抗剂，可用于治疗睡眠呼吸暂停症、嗜睡症、失眠、睡眠障碍、时差综合症、昼夜节律紊乱和与神经系统疾病相关的睡眠障碍。

  公开号：

  US20090163485A1
• 作为产物：
  描述：

  potassium ethyl xanthogenate 、 2-氯-3,5-二氟苯胺 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 5,7-difluoro-benzothiazole-2-thiol
  参考文献：
  名称：

  Development of Novel Rhodacyanine-Based Heat Shock Protein 70 Inhibitors

  摘要：

  背景：越来越多的证据表明，在人类乳腺肿瘤中过度表达的Hsp70在乳腺癌的肿瘤发生和进展以及其侵袭性表型中发挥作用。Hsp70构成了治疗该疾病的潜在治疗靶点。 方法：我们开发了一系列基于罗达氰基的Hsp70抑制剂，代表物为化合物1和6，其中现有Hsp70抑制剂（例如JG-40和JG-98）的阳离子吡啶-1-ium或噻唑-3-ium环被相应的苯并N-杂环取代。 结果：多条证据表明，这些苯并融合衍生物可能部分通过靶向Hsp70发挥其抗肿瘤活性。这些假定的抑制剂对乳腺癌细胞显示出不同的抗增殖效力（IC50低至0.25μM），而对非肿瘤性MCF-10A乳腺上皮细胞的IC50≥5μM。这与相应的Hsp70表达水平相关。通过蛋白质重折叠实验，我们确认这些药物有效地抑制了Hsp70的分子伴侣活性。此外，这些抑制剂有效地抑制了Hsp70的已知致癌客体蛋白，包括FoxM1、HuR和Akt的表达，这与它们的抗增殖效力相一致。支持Hsp70在调节蛋白质重折叠中的已知作用，这些衍生物诱导了自噬，表现为LC3B-I向LC3B-II的转化。值得注意的是，这些假定的Hsp70抑制剂不会引起Hsp90表达的补偿性升高，与先前报道的Hsp90抑制剂对Hsp70上调的效应形成对比。 结论：与化合物1和6显示出改善的微粒体稳定性的发现一起，这些结果表明这些假定的Hsp70抑制剂在促进癌症治疗新策略方面具有转化潜力。然而，这些苯并融合罗达氰是否作用于激酶或其他靶点仍不清楚，目前正在进行研究。

  DOI：

  10.2174/0929867328666210203204254

文献信息

• Heteroaryl derivatives as orexin receptor antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US07897627B2

  公开（公告）日：2011-03-01

  The present invention relates to compounds of formula wherein Ar, Het, R1 and n are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and are useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder and sleep disorders associated with neurological diseases.

  本发明涉及式I的化合物，其中Ar，Het，R1和n的定义如本文所述，以及药学上适宜的酸盐加成物，光学纯对映体，外消旋体或其间异构体混合物。式I的化合物是促进睡眠的受体拮抗剂，可用于治疗睡眠呼吸暂停症，嗜睡症，失眠症，睡眠障碍，时差综合症，昼夜节律紊乱和与神经系统疾病相关的睡眠障碍。
• US7897627B2
  申请人：——

  公开号：US7897627B2

  公开（公告）日：2011-03-01
• [EN] HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS HÉTÉROARYLES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR À OREXINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009080533A1

  公开（公告）日：2009-07-02

  The present invention relates to compounds of Formula (I), wherein Ar is an unsubstituted or substituted aryl or heteroaryl group, wherein the aryl and the heteroaryl group may be substituted by one or more substituents R2; R2 is hydroxy, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, C(O)-lower alkyl, nitro, NR,R,,, cyano, S-lower alkyl, SO2-lower alkyl, cycloalkyl, heterocycloalkyl, phenyloxy, benzyloxy, phenyl, NH-phenyl or heteroaryl, wherein the phenyl and heteroaryl group is unsubstituted or substituted by one or more substituents selected from lower alkyl or halogen; R,/R,, are independently from each other hydrogen or lower alkyl; R1 is hydrogen or lower alkyl; Het is a heteroaryl group, unsubstituted or substituted by one or more substituents selected from R3; R3 is hydroxy, halogen, =O, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, phenyl, lower alkoxy substituted by halogen, nitro, cyano, SO2-lower alkyl, cycloalkyl or heterocycloalkyl; n is 1 or 2; or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. It has been found that the compounds of formula (I) are orexin receptor antagonists and the related compounds may be useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.
• Development of Novel Rhodacyanine-Based Heat Shock Protein 70 Inhibitors
  作者：Chih-Shiang Chang、Vathan Kumar、Der-Yen Lee、Yeh Chen、Yu-Chieh Wu、Jing-Yan Gao、Po-Chen Chu

  DOI：10.2174/0929867328666210203204254

  日期：2021.9.8

  A growing body of evidence suggests that Hsp70, which is overexpressed in human breast tumors, plays a role in tumorigenesis and tumor progression in breast cancer as well as in its aggressive phenotypes. Hsp70 constitutes a potential therapeutic target in the treatment of this disease.

  We developed a new series of rhodacyanine-based Hsp70 inhibitors, represented by compounds 1 and 6, in which the cationic pyridin-1-ium or thiazol-3-ium ring of existing Hsp70 inhibitors (e.g., JG-40 and JG-98) was replaced by a corresponding benzo- fused N-heterocycle.

  Several lines of evidence suggest that these benzo-fused derivatives may exert their antitumor activities, in part, by targeting Hsp70. These putative inhibitors displayed differential antiproliferative efficacy against breast cancer cells (IC₅₀ as low as 0.25 μM) versus nontumorigenic MCF-10A breast epithelial cells (IC₅₀ ≥ 5 μM). This was correlated with the corresponding Hsp70 expression levels. Using a protein refolding assay, we confirmed that these agents effectively inhibited the chaperone activity of Hsp70. Moreover, these inhibitors effectively suppressed the expression of well-known oncogenic client proteins of Hsp70’s, including FoxM1, HuR, and Akt, which paralleled their antiproliferative efficacy. Supporting the established role of Hsp70 in regulating protein refolding, these derivatives induced autophagy, as manifested by the conversion of LC3B-I to LC3B-II. Notably, these putative Hsp70 inhibitors did not cause a compensatory elevation in Hsp90 expression, contrasting with the previously reported effects of Hsp90 inhibitors on Hsp70 upregulation.

  Together with the finding that compounds 1 and 6 showed improved microsomal stability, these results suggest the translational potential of these putative Hsp70 inhibitors to foster new strategies for cancer therapy. However, whether these benzo-fused rhodacyanines act on kinases or other targets remains unclear. It is currently under investigation.

  背景：越来越多的证据表明，在人类乳腺肿瘤中过度表达的Hsp70在乳腺癌的肿瘤发生和进展以及其侵袭性表型中发挥作用。Hsp70构成了治疗该疾病的潜在治疗靶点。 方法：我们开发了一系列基于罗达氰基的Hsp70抑制剂，代表物为化合物1和6，其中现有Hsp70抑制剂（例如JG-40和JG-98）的阳离子吡啶-1-ium或噻唑-3-ium环被相应的苯并N-杂环取代。 结果：多条证据表明，这些苯并融合衍生物可能部分通过靶向Hsp70发挥其抗肿瘤活性。这些假定的抑制剂对乳腺癌细胞显示出不同的抗增殖效力（IC50低至0.25μM），而对非肿瘤性MCF-10A乳腺上皮细胞的IC50≥5μM。这与相应的Hsp70表达水平相关。通过蛋白质重折叠实验，我们确认这些药物有效地抑制了Hsp70的分子伴侣活性。此外，这些抑制剂有效地抑制了Hsp70的已知致癌客体蛋白，包括FoxM1、HuR和Akt的表达，这与它们的抗增殖效力相一致。支持Hsp70在调节蛋白质重折叠中的已知作用，这些衍生物诱导了自噬，表现为LC3B-I向LC3B-II的转化。值得注意的是，这些假定的Hsp70抑制剂不会引起Hsp90表达的补偿性升高，与先前报道的Hsp90抑制剂对Hsp70上调的效应形成对比。 结论：与化合物1和6显示出改善的微粒体稳定性的发现一起，这些结果表明这些假定的Hsp70抑制剂在促进癌症治疗新策略方面具有转化潜力。然而，这些苯并融合罗达氰是否作用于激酶或其他靶点仍不清楚，目前正在进行研究。
• HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20090163485A1

  公开（公告）日：2009-06-25

  The present invention relates to compounds of formula wherein Ar, Het, R 1 and n are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and are useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder and sleep disorders associated with neurological diseases.

  本发明涉及以下公式的化合物，其中Ar，Het，R1和n的定义如本文所述，并且涉及适用于药物的酸盐、光学纯对映体、拉氏体或其二对映异构体混合物。公式I的化合物是促进睡眠激素受体拮抗剂，可用于治疗睡眠呼吸暂停症、嗜睡症、失眠、睡眠障碍、时差综合症、昼夜节律紊乱和与神经系统疾病相关的睡眠障碍。